TEVA Depends on This for Revenue Growth
Copaxone’s revenue trends
In 1H17, Teva Pharmaceutical Industries’ (TEVA) Copaxone reported revenues of ~$2.1 billion, or ~7% lower YoY (year-over-year). In 2Q17, Copaxone generated revenues of ~$1.0 billion, or ~10% lower YoY and ~5% higher QoQ (quarter-over-quarter).
Interested in TEVA? Don't miss the next report.
Receive e-mail alerts for new research on TEVA
Regional revenue trends
In 2Q17, in the US, Copaxone generated revenues of ~$843 million, compared with $955 million in 2Q16. In 2Q17, outside the US, Copaxone generated revenues of ~$180 million, compared with $186 million in 2Q16. The decline in sales volumes of Copaxone 20 mg in the US caused the decline in revenues in 2Q17. In 2Q17, the US contributed to ~82% of worldwide net Copaxone revenues, compared with ~84% in 2Q16.
In 2Q17, in US and European markets, more than 85% and 75% of Copaxone prescriptions, respectively, were with the 40 mg/ml version. The patients’ and physician’s choice of Copaxone 40 mg/ml primarily caused the high demand for this version.
TEVA’s US Orange book patents shielding the 20 mg/ml version of Copaxone expired in May 2014, while in the rest of the world, Copaxone 20 mg/ml patents expired in May 2015. Teva’s key business strategy for Copaxone is to maintain patients on the three-times-a-week 40 mg/ml version.
In 2Q17, Copaxone contributed to ~18% of TEVA’s net revenues. Copaxone (glatiramer acetate injection) is used for the treatment of individuals with relapsing forms of MS (multiple sclerosis).